SARCLISA® (ISATUXIM	AB-IRFC) PRESC		r Form				
Patient Name:				Date of Birth:			
Address:							
Phone:					\Box inches \Box cm	Weight:	🗆 lbs 🗆 kg
Clinical Information Primary Diagnosis Description: ICD-10 Code:							
Is this the first dose? YES – Date of first dose: NO – Date of next dose due: SARCLISA®(isatuximab-irfc) Prescription							
Sarclisa (isatuximab-irfc) 10 mg/kg in 250 mL sodium chloride 0.9% as an intravenous infusion. Dose based on weight taken prior to each cycle. Cycle 1: Administer on Days 1, 8, 15, and 22 (weekly) Cycle 2 and beyond: Administer on Days 1, 15 (every 2 weeks) Other:							
1 st Infusion	Dilution Volume 250 mL	Initial Rate 25 mL/hr		ision reaction minutes	Rate Increase by25 mL/hr every 30 minutes		Max Rate 150 mL/hr
2 nd Infusion	250 mL	50 mL/hr		minutes	100 mL/hr every 30 minutes		200 mL/hr
Subsequent Infusions	250 mL	200 mL/hr	-		-		200 mL/hr
Anaphylaxis Kit Dosage: • Epinephrine 0.3 mg (> 30 kg), 0.15 mg (15 to 30 kg), or 0.01 mg/kg (< 15 kg) SQ or IM x 1; repeat x 1 in 5 to 15 min PRN. • Diphenhydramine 25 mg (> 30 kg) or 1.25 mg/kg (≤ 30 kg – 25mg max dose) IV or IM; repeat x 1 in 15 min PRN no improvement. • 0.9% Sodium Chloride 500 mL (> 30 kg) or 250 mL (≤ 30 kg) IV at KVO rate PRN anaphylaxis. Pre-Medication Orders □ Dexamethasone 20 mg IV on the days of SARCLISA and/or carfilzomib infusions, orally on day 22 in cycle 2 and beyond, and orally on day 23 in all cycles. □ Acetaminophen 650 mg PO 30 min before infusion. Patient may decline. □ Diphenhydramine 25 mg PO 30 min before infusion. Patient may decline. □ Diphenhydramine 25 mg PO 30 min before infusion. Patient may decline. □ Other: □ V Flush Orders □ Peripheral: 0.9% Sodium Chloride 2 to 3 mL pre-/post-use and 10 to 20 mL pre-/post-lab draw. Heparin (100 unit/mL) 3 to 5 mL post-use. □ Implanted Port: 0.9% Sodium Chloride 5 to 10 mL pre-/post-use and 10 to 20 mL pre-/post-lab draw. Heparin (100 unit/mL) 3 to 5 mL post-use. □ As the orders For maintenance, heparin (100 unit/mL) 3 to 5 mL every 24 hr. if accessed or weekly to monthly if not accessed. Lab Orders							
Prescriber Signature: Date:							
Prescriber Name:		Prescr	iber Inform P	ation hone:		Fax:	
Address:			N	IPI:			
City, State: Zip:			c	Office Contact:			
Fax completed form, insurance information, and clinical documentation to:							
CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that do not require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state laws. IMPORTANT WARNING: This message is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.							